Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: A meta-analysis of randomized controlled trials

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 2, 2016, Pages 232-244

  Patel, Leena ^a   Bernard, Lisa M ^a   Elder, Grahame J ^b,c  

^a Department of Data Analytics and Evidence Synthesis   (Canada)

^b WESTMEAD HOSPITAL   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Calcium; Chronic kidney disease; Hospitalization; Humans; Meta analysis; Mortality; Phosphate binders; Randomized controlled trials as topic; Sevelamer

Indexed keywords

ALKALINE PHOSPHATASE; BICARBONATE; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM BASED BINDING AGENT; CALCIUM CARBONATE; CALCIUM SALT; CHOLESTEROL; FETUIN A; FIBROBLAST GROWTH FACTOR 23; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CALCIUM DERIVATIVE; CHELATING AGENT;

BLOATING; BLOOD VESSEL CALCIFICATION; BONE DENSITOMETRY; CALCINOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CONSTIPATION; DIARRHEA; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; META ANALYSIS; NAUSEA; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VOMITING; ADVERSE EFFECTS; BLOOD; CHI SQUARE DISTRIBUTION; COMPLICATION; MORTALITY; ODDS RATIO; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; TREATMENT OUTCOME;

BIOMARKERS; CALCIUM COMPOUNDS; CHELATING AGENTS; CHI-SQUARE DISTRIBUTION; HUMANS; HYPERPHOSPHATEMIA; ODDS RATIO; PHOSPHATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEVELAMER; TREATMENT OUTCOME;

EID: 84957081149     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06800615     Document Type: Review

References (50)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic KidneyDisease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 76[113]: S1-S130, 2009.
2. Felsenfeld AJ, Levine BS, Rodriguez M: Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease [published online ahead of print August 25,2015]. Semin Dial 10.1111/sdi.12411.
3. Lopes AA, Tong L, Thumma J, Li Y, Fuller DS, Morgenstern H, Bommer J, Kerr PG, Tentori F, Akiba T, Gillespie BW, Robinson BM, Port FK, Pisoni RL: Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Evaluation of possible confounding by nutritional status. AmJ KidneyDis 60: 90-101, 2012.
4. Cannata-Andía JB, Fernández-Martín JL, Locatelli F, London G, Gorriz JL, Floege J, Ketteler M, Ferreira A, Covic A, Rutkowski B, MemmosD, Bos WJ, Teplan V, Nagy J, Tielemans C, VerbeelenD, Goldsmith D, Kramar R, Martin PY, Wü thrich RP, Pavlovic D, Benedik M, Sánchez JE, Martínez-Camblor P, Naves-Díaz M, Carrero JJ, Zoccali C: Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 84: 998-1008,2013.
5. Tonelli M, Pannu N,Manns B: Oral phosphate binders in patients with kidney failure. N Engl J Med 362: 1312-1324, 2010.
6. Hill KM,Martin BR,Wastney ME, McCabe GP,Moe SM,Weaver CM, PeacockM: Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 83: 959-966, 2013.
7. Bellasi A, Kooienga L, Block GA: Phosphate binders: New products and challenges. Hemodial Int 10: 225-234, 2006.
8. Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF: Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2: CD006023, 2011.
9. Jamal SA, Vandermeer B, Raggi P,MendelssohnDC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT: Effect of calciumbased versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-analysis. Lancet 382: 1268-1277, 2013.
10. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration,2011. Available at: http://www.handbook.cochrane.org. Accessed September 23, 2014.
11. Lefebvre C, Manheimer E, Glanville J: Chapter 6: Searching for Studies. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration, 2011. Available at: http://www.handbook.cochrane.org. Accessed September 23, 2014.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 327: 557-560, 2003.
13. R Core Team: R: A Language and Environment for Statistical Computing, Vienna, Austria, R Foundation for Statistical Computing,2013.
14. Barreto DV, Barreto FC, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME: Phosphate binder impact on bone remodeling and coronary calcification-results fromthe BRiC study. Nephron Clin Pract 110: c273-c283, 2008.
15. Peres AT, Dalboni MA, Canziani ME, Manfredi SR, Carvalho JT, Batista MC, Cuppari L, Carvalho AB, Moysés RM, Guimarães N, Jorgetti V, Andreoli MC, Draibe SA, Cendoroglo M: Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodial Int 13: 271-277, 2009.
16. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701, 1999.
17. Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S: Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant 24: 278-285, 2009.
18. Koiwa F, Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M, Shigematsu T; ROD 21 Clinical Research Group: Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 9: 340-346,2005.
19. Liu YL, LinHH, Yu CC, Kuo HL, Yang YF, Chou CY, LinPW, Liu JH, Liao PY, Huang CC: A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail 28: 701-707, 2006.
20. Sadek T, Mazouz H, Bahloul H, Oprisiu R, El Esper N, El Esper I, Boitte F, Brazier M, Moriniere P, Fournier A: Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: An open-label, randomized study. Nephrol Dial Transplant 18: 582-588, 2003.
21. De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E, Iacono G, Ciacci C, Savica V, Cirillo M: Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 19[Suppl 9]: S108- S114, 2006.
22. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, PelhamRW, Cleveland MV, Muenz LR, He DY, Nolan CR: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65: 1914-1926, 2004.
23. RussoD, Miranda I, Ruocco C, Battaglia Y, Buonanno E,Manzi S, Russo L, Scafarto A, Andreucci VE: The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72: 1255-1261, 2007.
24. Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ: Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 25: 785-791, 2004.
25. ChertowGM, Dillon M, Burke SK, StegM, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51: 18-26, 1999.
26. Hervás JG, Prados D, Cerezo S: Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison with calcium acetate. Kidney Int Suppl 85: S69-S72,2003.
27. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824, 2005.
28. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441, 2007.
29. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252,2002.
30. AsmusHG, Braun J, Krause R, Brunkhorst R,Holzer H, SchulzW, Neumayer HH, Raggi P, Bommer J: Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 20:1653-1661, 2005.
31. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 149: 820-825, 2005.
32. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM: Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 20: 764-772, 2005.
33. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz- Buxo JA, Budoff M; CARE-2 Investigators: A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51: 952-965, 2008.
34. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH; Sevelamer Study Group: Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19:405-412, 2008.
35. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130-1137, 2007.
36. Cancela AL, Oliveira RB, Graciolli FG, dos Reis LM, Barreto F, Barreto DV, Cuppari L, Jorgetti V, Carvalho AB, Canziani ME, Moysés RM: Fibroblast growth factor 23 in hemodialysis patients: Effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract 117: c74-c82, 2011.
37. Chennasamudram SP, Noor T, Vasylyeva TL: Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis. J Ren Care 39: 82-89, 2013.
38. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM: Effects of phosphate binders in moderate CKD. J AmSoc Nephrol 23: 1407-1415, 2012.
39. Lin YF, Chen YM, Hung KY, Chu TS, Kan WC, Huang CY, Lin SL, Kao TW,Huang JW, ChiangWC, Yen CJ, Tsai TJ,Wu KD,WuMS: Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. J Formos Med Assoc 109: 663-672, 2010.
40. Lin YF, Chien CT, Kan WC, Chen YM, Chu TS, Hung KY, Tsai TJ, Wu KD, Wu MS: Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: A randomized, open-label, parallel-group study. Clin Drug Investig 31: 257-267, 2011.
41. Navarro-Gonzá lez JF, Mora-Fernández C, Muros de Fuentes M, Donate-Correa J, Caza~na-Pé rez V, García-Pé rez J: Effect of phosphate binders on seruminflammatory profile, solubleCD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol 6: 2272-2279, 2011.
42. Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators: Mortality in kidney disease patients treated with phosphate binders: A randomized study. Clin J AmSoc Nephrol 7: 487-493,2012.
43. Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A: Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57: 422-431, 2011.
44. Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A; INDEPENDENT Study Investigators: Sevelamer versus calcium carbonate in incident hemodialysis patients: Results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62: 771-778, 2013.
45. Ahmed W, Rizwan H, Akram M, Khan S, Haider S, Abad R: Comparative efficacy of sevelamer hydrochloride versus calcium acetate on bone biomarkers in patients with end stage renal disease on hemodialysis. Pak J Med Health Sci 8: 769-771, 2014.
46. Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ: A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 68: 386-391, 2007.
47. Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, Plone M, Pritchard N: A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 24: 3794-3799, 2009.
48. Di Micco L, Salvi P, Bellasi A, Sirico ML, Di Iorio B: Subendocardial viability ratio predicts cardiovascular mortality in chronic kidney disease patients. Blood Purif 36: 26-28, 2013.
49. Chue CD, Townend JN, MoodyWE, ZehnderD,Wall NA,Harper L, Edwards NC, Steeds RP, Ferro CJ: Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 24: 842-852, 2013.
50. Block GA, Ix JH, Ketteler M, Martin KJ, Thadhani RI, Tonelli M, Wolf M, Jüppner H, Hruska K, Wheeler DC: Phosphate homeostasis in CKD: Report of a scientific symposiumsponsored by the National Kidney Foundation. Am J Kidney Dis 62: 457-473,2013.